{
    "nctId": "NCT01929811",
    "briefTitle": "NeoMET Study in Neoadjuvant Treatment of Breast Cancer",
    "officialTitle": "Neoadjuvant Treatment of TEC Versus TEC Plus Metformin in Breast Cancer\uff1aA Prospective, Randomized Trial",
    "overallStatus": "TERMINATED",
    "conditions": "pCR Rate, BCT Rate, Safety",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 92,
    "primaryOutcomeMeasure": "pathologic complete response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* women aged \u226518 years and \\< 70 years with life expectancy \\> 12 months\n* Measurable disease in breast or axillary lymph node, histologically confirmed invasive breast cancer by core needle biopsy, T\u22652cm or stage IIb or stage III according AJCC classification, fine-needle aspiration is encouraged to every patient with metastasis suspicious nodes;\n* Biopsy specimens are available for ER, PgR, Her2 and proliferation biomarker detection;\n* Adequate bone marrow function: Neutrophil \u2265 1.5\\*109/L; Hb \u2265 100g/L; PLT \u2265 80\\*109/L;\n* Adequate liver and renal function:\n* Serum AST \u2264 90U/L\n* Bilirubin \u2264 upper limit of normal (UNL) range\n* Serum creatinine \u2264110 umol/L\uff0ccalculated creatinine clearance should be \u2265 60 mL/min;\n* BUN \u2264 7.1mmol/L;\n* Has ECOG Performance Score 0-1;\n* BMI \u2265 25kg/m2 or hyperglycemia or hyperlipemia or hypertension;\n* Willing to take biopsy before neoadjuvant chemotherapy and patients must be accessible for treatment and follow-up;\n* Women with potential child-bearing must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable method of birth control to avoid pregnancy for the duration of the study;\n* Written informed consent according to the local ethics committee requirements.\n\nExclusion Criteria:\n\n* Prior systemic or loco-regional treatment of breast cancer, including chemotherapy;\n* Metastatic breast cancer;\n* With a history of malignant tumor except uterine cervix cancer in situ or skin basal cell carcinoma;\n* Patients with medical conditions that indicate intolerant to neoadjuvant therapy and related treatment, including uncontrolled pulmonary disease, severe infection, active peptic ulcer, coagulation disorder, connective tissue disease or myelo-suppressive disease;\n* Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is known to be HIV positive;\n* Contraindication for using dexamethasone, chemotherapy agents or metformin;\n* History of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction; poorly controlled hypertension (systolic BP \\>180mmHg or diastolic BP \\>100mmHg);\n* Has peripheral neuropathy \u2265 grade 1;\n* Patient is pregnant or breast feeding (not willing to stop breast feeding);\n* Not willing to take core needle biopsy or patients with psychiatric disorder or other diseases leading to incompliance to the therapy\n* Known severe hypersensitivity to any drugs in this study;\n* Treatment with any investigational drugs within 30 days before the beginning of study treatment.\n* History of lactic or other metabolic acidosis\n* Consumption of \\> 3 alcoholic beverages per day (on average)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}